Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
Manfred Kaufmann(Goethe University Frankfurt), Gabriel N. Hortobágyi(Goethe University Frankfurt), Aron Goldhirsch(Goethe University Frankfurt), Suzy Scholl(Goethe University Frankfurt), Andreas Makris(Goethe University Frankfurt), Pinuccia Valagussa(Goethe University Frankfurt), Jens‐Uwe Blohmer(Goethe University Frankfurt), W. Eiermann(Goethe University Frankfurt), Raimund Jackesz(Goethe University Frankfurt), W. Jonat(Goethe University Frankfurt), Annette Lebeau(Goethe University Frankfurt), Sibylle Loibl(Goethe University Frankfurt), William R. Miller(Goethe University Frankfurt), Sigfried Seeber(Goethe University Frankfurt), Semiglazov Vf(Goethe University Frankfurt), Roy E. Smith(Goethe University Frankfurt), Rainer Souchon(Goethe University Frankfurt), Vered Stearns(Goethe University Frankfurt), Michael Untch(Goethe University Frankfurt), Gϋnter von Minckwitz(Goethe University Frankfurt)
Cited by 720Open Access
Abstract
Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
Related Papers
No related papers found
Powered by citation graph analysis